Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichlorethanol SCHEMBL325071 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL7261325 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL291748 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL1436780 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL8522341 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL16162174 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL4450822 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL88329 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL762332 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR | |
| Trichlorethanol SCHEMBL6898269 | 1.00 | LMNA (0.33) | LMNATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-114641314-B | Method for treating or preventing chronic kidney disease | 日本烟草产业株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-117999272-A | Peptides | ＡＧＣ株式会社 | 2024-05-07 | — | — | CN | disclosed |
| EP-4342466-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-111757877-B | Methyllactam ring compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-10-27 | — | — | CN | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2023048236-A1 | PEPTIDE | ＡＧＣ株式会社 | 2023-03-30 | — | — | WO | disclosed |
| EP-4026562-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026564-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-0282984-A1 | 23-Phenylsteroids | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-09-21 | — | — | EP | disclosed |
| CN-88100804-A | Substituted amine derivatives, their preparation and use | — | 1988-08-24 | — | — | CN | disclosed |
| EP-0252727-A1 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1988-01-13 | — | — | EP | disclosed |
| US-4711958-A | HYPOTENSIVE AGENTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1987-12-08 | — | — | US | disclosed |
| EP-0244083-A2 | Amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| US-4656269-A | RENIN INHIBITORY EFFECT WHEN ADMINISTERING ORALLY; HYPOTENSIVE AGENTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1987-04-07 | — | — | US | disclosed |
| EP-0206807-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-12-30 | — | — | EP | disclosed |
| EP-0200406-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
| EP-0190891-A2 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
| EP-0181110-A2 | Histidine derivatives as renin inhibitors | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | SLC5A1, SLC5A2, REN | LMNA 3176/4885TDP1 4648/4885TP53 4793/4885 |
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC5A6 | LMNA 4208/4885TDP1 4440/4885TP53 4754/4885 |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | DPP4, SLC5A1, SLC5A2 | LMNA 4413/4885TDP1 2764/4885TP53 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.